-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2023-505901-17-00
5
2020-04-24
Acute Myeloid Leukemia (LMA) with FLT3 mutation
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2024-519469-23-00
4
2025-10-20
Severe Asthma
-
2024-516412-17-00
5
2025-08-26
Developmental and Epileptic Encephalopathies (DEE)
-
2024-519191-90-00
4
2025-07-02
Immunoglobulin Light-Chain (AL) Amyloidosis
-
2024-518687-12-00
4
2025-06-19
Pulmonary Arterial Hypertension (PAH)
-
2024-515773-99-00
4
2025-05-26
Pulmonary Hypertension
-
2024-514064-17-00
3
2025-05-23
Pulmonary Arterial Hypertension
-
2024-516811-25-00
4
2025-05-15
Parkinson Disease
-
2023-505601-16-00
5
2025-04-22
Chronic Migraine
-
2024-512946-41-00
5
2025-03-05
Menstrual Migraine
-
2024-515538-34-00
10
2025-02-27
Head and Neck Squamous Cell Carcinoma
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-519087-41-00
5
2025-02-03
Breast cancer is the most common form of cancer among women in North A
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-513991-16-00
4
2025-01-17
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-511933-36-00
4
2025-01-02
Diffuse cutaneous systemic sclerosis (dcSSc)